Targeting Innate Allorecognition Via CD47-Sirpa Prolongs Cardiac Allograft Survival In Presensitized Recipients (TTS 2026) - Sep 17, 2026 - Pres time: Sep 22, 2026; 11:00 AM - 12:00 PM; Location: Room C3.4-C3.5; 333; "More specific therapeutic strategies, such as CTLA4-Ig (belatacept) with long-term benefits exist; however, they cause higher acute rejection rates without the addition of calcineurin inhibitors (CNI)... Disrupting innate allorecognition is a promising target and can be combined with costimulatory blockade to achieve CNI-free immunosuppression and long-term graft survival. Further studies will determine how CD47 signaling drives monocyte differentiation and directs cytokine production."
Cardiovascular • Transplant Rejection • CD8 • IFNG • IL10 • IL12A • SIRPA
|
|
Berkay Demirors1; Gang Zhang1; Latha Halesha1; Neda Feizi1; Canxiang Lin1; Amanda Williams1; Parmjeet Randawa1; Khodor Abou-Daya1; Aravind Cherukuri1; Faruk Sacirbegovic1; Martin Oberbarnscheidt1
|